Newsletter | January 28, 2024

01.28.24 -- Samsung Bioepis Releases Q124 US Biosimilars Report


Measurement System Analysis Using Continuous Gage R&R Studies, Part 3

This is the third article in a series of three articles. It continues the discussion of measurement system analysis using continuous gage R&D studies by sharing a generic example using Minitab. Study setup, the role of the study director, analysis, and case studies are examined.


Reliable Components For The Life Cycle Of Your Injectable Drug Product

As drug products increase in complexity, become more specialized, and trend toward self-administration, it is more important than ever to have a reliable drug closure system.


Samsung Bioepis Releases First Quarter 2024 U.S. Biosimilar Market Report

Formycon Ranibizumab Biosimilar FYB201/CIMERLI Achieved A Market Share Of 38% In The U.S. In Dec 2023

Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation & Regulation In The U.S.

Boan Biotech Obtains ANVISA GMP Certification

First Subject Dosed For Phase 1 Clinical Trial Of Henlius’ Ipilimumab Biosimilar HLX13

Celltrion USA Announces Launch Of Additional Doses For YUFLYMA (adalimumab-aaty) In The U.S

Sandoz Announces Agreement To Acquire CIMERLI® Business From Coherus, Strengthening Position In US Market

All Subjects Enrolled For Intl Phase 3 Study Of Boan’s Denosumab

Biosimilars Forum Welcomes Teva As Newest Member


A Gloveless Aseptic Filling System For Vials, Syringes, And Cartridges